Clinical trials: Relapse Multiple Myeloma
Multiple Myeloma
A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D Chimeric antigen receptor (CAR) T-cells in patients with relapsed or refractory multiple myeloma who received…
- Trial name
- NCT05998928
- Testing
- Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Multiple Myeloma
Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
This is an open label, single-arm, Phase 2 study to evaluate the efficacy and safety of Anti-BCMA/FcRL5 CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture.
- Trial name
- NCT06759181
- Testing
- anti-BCMA/FcRL5 CAR T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuzhou Medical University
Multiple Myeloma
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to show that subcutaneous (SC) administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to intravenous (IV) administration of daratumumab (Dara…
- Trial name
- NCT03277105
- Testing
- Dara SC, Dara IV
- Where
- 146 sites in United States, Australia and 16 more
- Volunteers
- 522 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
The primary purpose of this dose escalation study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LGH447 as a single agent when administered orally once daily to adult patients with…
- Trial name
- NCT01456689
- Testing
- LGH447, midazolam
- Where
- 8 sites in United States, Germany and 2 more
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed/Refractory Multiple Myeloma
Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP
Multicentre, open label, uncontrolled, phase I pharmacokinetic study, to determine the Maximum Tolerated Dose (MTD) of APO010 administered intravenously on D1, D8 and D15 followed by a one-week drug rest, in patients with…
- Trial name
- SMR-3184 (NCT03196947)
- Testing
- APO010
- Where
- Denmark
- Volunteers
- 1 people
- Sponsor
- Allarity Therapeutics
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A phase 3, randomized, open-label, parallel-controlled, multi-center study comparing TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in subjects with relapsed or refractory multiple myeloma who received…
- Trial name
- NCT03952091
- Testing
- TJ202, Lenalidomide and Dexamethasone, Lenalidomide and Dexamethasone
- Where
- 41 sites in China, Taiwan
- Volunteers
- 289 people
- Sponsor
- TJ Biopharma Co., Ltd.
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat, pomalidomide, and dexamethasone and to establish the recommended Phase 2 dose for combination treatment to…
- Trial name
- NCT07150104
- Testing
- Belantamab mafodotin, Nirogacestat, Pomalidomide
- Where
- 10 sites in Brazil, Canada and 6 more
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline
Acute Myeloid Leukemia, Acute Leukemia
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
New conditioning regimens are still needed to maximize efficacy and limit treatment-related deaths of allogeneic transplantation for advanced hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, Malignant Lymphoma
- Trial name
- NCT01499147
- Testing
- fludarabine/busulfan, fludarabine/ melphalan, ATG
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Illinois Chicago
Multiple Myeloma, Solid Tumors
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer.
- Conditions
- Multiple Myeloma, Solid Tumors, Non-Small Cell Lung Cancer
- Trial name
- NCT01457417
- Testing
- DKN-01
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Leap Therapeutics, Inc.
Relapsed Refractory Multiple Myeloma (RRMM)
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
This is a phase 1 study to find the recommended dose and schedule of mezigdomide and talquetamab in relapsed and refractory multiple myeloma (RRMM), and to test the effects of the drugs on cancer.
- Trial name
- MAGENTA (NCT07032714)
- Testing
- Talquetamab, Mezigdomide, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Relapsed and/or Refractory Multiple Myeloma
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
All patients with multiple myeloma (MM) are destined to relapse even with the best available approved agents. Median OS from diagnosis in the current era is reported at 5.4 years.
- Trial name
- NCT03140943
- Testing
- Carfilzomib, Thalidomide and Dexamethasone
- Where
- 4 sites in Hong Kong, Singapore and 2 more
- Volunteers
- 100 people
- Sponsor
- National University Hospital, Singapore
Multiple Myeloma
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
The primary purpose of the study is to determine the safety and efficacy and to generate PK and biomarker data for the combination of Pomalidomide and low-dose Dexamethasone in patients with relapsed or refractory multiple…
- Trial name
- NCT02045017
- Testing
- Pomalidomide and Dexamethasone
- Where
- 22 sites in Austria, France and 6 more
- Volunteers
- 81 people
- Sponsor
- Celgene
Lymphoma, Refractory B-Cell Lymphoma
Study of CAR-T Therapy in Older Patients
This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life.
- Conditions
- Lymphoma, Refractory B-Cell Lymphoma, Lymphoma, B-Cell, DLBCL NOS
- Trial name
- NCT04300998
- Testing
- Activities of Daily Living/ADLs, Instrumental Activity of Daily Living, Timed Up and Go
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed Refractory Multiple Myeloma (RRMM)
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
The goal of this clinical trial is to find out how well a combination of two medicines (mezigdomide and elranatamab) works in treating patients with refractory/relapsed multiple myeloma.
- Trial name
- MELT-MM (NCT06645678)
- Testing
- Elranatamab, Mezigdomide, Dexamethasone
- Where
- 7 sites in Singapore, South Korea
- Volunteers
- 75 people
- Sponsor
- YOUNGIL KOH
Multiple Myeloma, Relapsed Cancer
Plan Development for Giving Teclistamab in the Outpatient Setting
This is a pilot study to develop an outpatient-based process for the administration of teclistamab for for relapsed/refractory multiple myeloma patients and to evaluate the burden on caregivers of patients receiving outpatient…
- Conditions
- Multiple Myeloma, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT06251076
- Testing
- Teclistamab, Tocilizumab
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University Health Network, Toronto
Multiple Myeloma
Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
This study will assess the efficacy of daratumumab in combination with ixazomib and dexamethasone as second line treatment for relapsed Multiple Myeloma patients.
- Trial name
- DARIA (NCT03746652)
- Testing
- Daratumumab, Ixazomib, Dexamethasone
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- Hellenic Society of Hematology
Multiple Myeloma
Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma
This is a open-label to determine the efficacy and safety of IM21 CAR-T cells in adult with R/R multiple myeloma.
- Trial name
- NCT05478343
- Testing
- IM21 CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Multiple Myeloma
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can…
- Trial name
- LINKER-MM1 (NCT03761108)
- Testing
- Linvoseltamab
- Where
- 40 sites in United States, Belgium and 5 more
- Volunteers
- 387 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma, Multiple Myeloma in Relapse
Marizomib Central Nervous System (CNS)
This research is being done to test whether the investigational drug marizomib is safe and effective when used in combination with standard of care drugs for the treatment of multiple myeloma.
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Trial name
- NCT05050305
- Testing
- Marizomib, Pomalidomide, Dexamethasone
- Where
- 2 sites in United States
- Sponsor
- Dana-Farber Cancer Institute